|
GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2024年度 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/4461
|
タイトル: | Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid MRI |
その他のタイトル: | EOB造影MRIの肝細胞相を用いた切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマ ブ併用療法の治療効果予測 |
著者: | Kunichika, Hideki Minamiguchi, Kiyoyuki Tachiiri, Tetsuya Shimizu, Kozo Taiji, Ryosuke Yamada, Aya Nakano, Ryota Irizato, Mariko Yamauchi, Satoshi Marugami, Aki Marugami, Nagaaki Kishida, Hayato Nakagawa, Hiroyuki Takewa, Megumi Kageyama, Ken Yamamoto, Akira Ueshima, Eisuke Sofue, Keitaro Kita, Ryuichi Kurakami, Hiroyuki Tanaka, Toshihiro |
キーワード: | hepatocellular carcinoma atezolizumab plus bevacizumab magnetic resonance imaging hepatobiliary phase coefficient of variation |
発行日: | 2024年6月 |
出版者: | MDPI |
引用: | Cancers. 2024 Jun, vol.16, no.12, article no.2275 |
抄録: | Background: This study aimed to examine whether the coefficient of variation (CV) in the hepatobiliary-phase (HBP) of Gd-EOB-DTPA-MRI could be an independent predictive factor
for tumor progression. Methods: Patients who underwent Gd-EOB-DTPA-MRI before Atezolizumab/
bevacizumab therapy at six affiliated institutions between 2018 and 2022 were included. CV for each patient was calculated as the mean value for up to five tumors larger than 10 mm, and CV of the whole tumor was calculated using LIFEx software. The tumor response was evaluated within 6–10 weeks. The primary endpoint was to investigate the predictive factors, including CV, related to tumor progression using logistic regression analysis. The secondary endpoints were tumor
response rate and progression-free survival (PFS) based on CV. Results: Of the 46 enrolled patients, 13 (28.3%) underwent early progressive disease. Multivariate analysis revealed that a high CV (≥0.22) was an independent predictive factor for tumor progression (p = 0.043). Patients with a high CV had significantly frequent PD than those with a low CV (43.5 vs. 13.0%, p = 0.047). Patients with a high CV tended to have shorter PFS than those with a low CV (3.5 vs. 6.7 months, p = 0.071). Conclusion: Quantitative analysis using CV in the HBP of Gd-EOB-DTPA-MRI may be useful for predicting tumor progression for atezolizumab/bevacizumab therapy. |
内容記述: | 権利情報:© 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
URI: | http://hdl.handle.net/10564/4461 |
ISSN: | 2072-6694 |
DOI: | https://doi.org/10.3390/cancers16122275 |
学位授与番号: | 24601甲第966号 |
学位授与年月日: | 2025-03-14 |
学位名: | 博士(医学) |
学位授与機関: | 奈良県立医科大学 |
出現コレクション: | 2024年度
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|